Journey Medical (DERM) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Journey Medical (DERM) over the past year, gaining 5.4% versus a loss of 21.2%. Journey Medical is the larger company by market cap ($168.8 million vs $159.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | MSLE |
|---|---|---|
| Share price | $5.98 | $7.51 |
| Market cap | $168.78M | $159.23M |
| 1-day change | +0.50% | -1.63% |
| YTD return | -22.83% | +29.76% |
| 1-year return | -21.19% | +5.44% |
| 5-year return | — | -48.93% |
| EPS (TTM) | $-0.22 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $13.40 |
| 52-week low | $4.31 | $5.30 |
| Distance from 52-week high | -37.41% | -43.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +129.93% | +249.77% |
| Average volume | 182.16K | 51.29K |
| Shares outstanding | 22.22M | 21.22M |
| Employees | 58 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed DERM by 26.6 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
DERM vs MSLE FAQ
Which is bigger, Journey Medical or Satellos Bioscience?
Journey Medical (DERM) is larger, with a market capitalization of $168.78M compared with $159.23M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, DERM or MSLE?
MSLE returned +5.44% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.